PMPascal Millet

Pascal Millet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pascal Millet has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmaceutical development and optimization of azithromycin suppository for paediatric use

    by Tina Kauss, Alexandra Gaubert, Chantal Boyer, Boubakar B. Ba, Muriel Manse, Stephane Massip, Jean-Michel Léger, Fawaz Fawaz, Martine Lembege, Jean-Michel Boiron, et al.


    • 16 August 2010
      • Vol. 395, 198-204

    Fixed artesunate-amodiaquine combined pre-formulation study for the treatment of malaria.

    by Tina Kauss, Fawaz Fawaz, Michel Guyot, Anne-Marie Lagueny, Isabelle Dos Santos, François Bonini, Piero Olliaro, Antonella Caminiti, Pascal Millet

    Artemisinin-based combination therapies, including artesunate (AS) + amodiaquine (AQ), are the currently recommended first-line treatment of uncomplicated falciparum malaria. Fixed-dose co-formulations offer logistic and adherence advantages. This paper reports the initial research phase of the pre-development process of an AS-AQ formulation, further developed by the Drug for Neglected Diseases Initiative (DNDi). Results demonstrate that AS and AQ are not compatible, and AS degradation is related to three main parameters: water content (>1%), elevated temperature (80 degrees C in dry condition) and possibly the 4-aminoquinoline moiety. Furthermore, AS and AQ incompatibility led to AS degradation and pharmaco-technical changes in classical wet granulation tablets. Both active principles are stable as dry powders. These investigations led to further development of various co-formulations, including the bilayer tablet currently on the market.